Related Experiment Video
Updated: Nov 7, 2025

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia
Published on: June 28, 2018
Antimicrobial Susceptibility among Pathogens Isolated in Early- versus Late-Onset Ventilator-Associated Pneumonia
Hend Ben Lakhal1,2, Aymen M'Rad2, Thierry Naas3,4
1Service de Reanimation, Centre Hospitalier de Chartres, 4, Rue Claude-Bernard, 28630 Le Coudray, France.
Abstract:
Ventilator-associated pneumonia (VAP) is associated with increased hospital stay and high morbidity and mortality in critically ill patients. The aims of this study were to (i) determine the incidence of multidrug-resistant (MDR) pathogens in the first episodes of VAP and to assess potential differences in bacterial profiles of subjects with early- versus late-onset VAP. This was a retrospective cohort study over a period of 18 months including all patients who had a first episode of VAP confirmed by positive bacterial culture. Subjects were distributed into two groups according to the number of intubation days: early-onset VAP (<5 days) or late-onset VAP (≥5 days). The primary endpoint was the nature of causative pathogens and their resistance profiles. Sixty patients were included, 29 men and 31 women, with an average age of 38 ± 16 years. The IGS 2 at admission was 40.5 [32-44] and APACHE was 19 [15-22]. Monomicrobial infections were diagnosed in 77% of patients (n = 46). The most frequently isolated bacteria were A. baumannii, 53% (n = 32); P. aeruginosa in 37% (n = 22); Enterobacterales in 28% (n = 17) and S. aureus in 5% (n = 3). Ninety-seven percent of the bacteria were MDR. The VAP group comprised 36 (60%) episodes of early-onset VAP and 24 (40%) episodes of late-onset VAP. There was no significant difference in the distribution of the bacterial isolates, nor in terms of antibacterial resistances between early- and late-onset VAPs. Our data support recent observations that there is no microbiological difference in the prevalence of potential MDR pathogens or in their resistance profiles associated with early- versus late-onset VAPs, especially in countries with high rates of MDR bacteria.
Insights
Multidrug-resistant (MDR) pathogens are common in ventilator-associated pneumonia (VAP). Early-onset and late-onset VAP show similar bacterial profiles and resistance patterns, challenging traditional distinctions.
Area of Science:
- Critical Care Medicine
- Infectious Diseases
- Microbiology
Background:
- Ventilator-associated pneumonia (VAP) significantly increases hospital stay, morbidity, and mortality in critically ill patients.
- Understanding the microbiological characteristics of VAP, particularly concerning multidrug-resistant (MDR) pathogens, is crucial for effective treatment strategies.
Purpose of the Study:
- To determine the incidence of MDR pathogens in first-episode VAP.
- To compare the bacterial profiles and resistance patterns between early-onset VAP (<5 days intubation) and late-onset VAP (≥5 days intubation).
Main Methods:
- Retrospective cohort study over 18 months.
- Inclusion of patients with a first episode of VAP confirmed by positive bacterial culture.
- Categorization into early-onset (<5 days) and late-onset (≥5 days) VAP groups based on intubation duration.
Main Results:
- Sixty patients were included; 97% of isolated bacteria were MDR.
- Most frequent pathogens: *Acinetobacter baumannii* (53%), *Pseudomonas aeruginosa* (37%), Enterobacterales (28%).
- No significant difference in bacterial isolate distribution or antimicrobial resistance profiles between early- and late-onset VAP groups.
Conclusions:
- The study found no significant microbiological differences between early- and late-onset VAP in terms of MDR pathogen prevalence or resistance.
- These findings suggest that VAP management may not need to differentiate based on onset timing, especially in regions with high MDR rates.
More Related Videos
09:26Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Antimicrobial Effectiveness
Pneumonia II: Pathophysiology
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....